Keyword Search Year None20222021202020192018 Date Title PDF Version 11/17/22 Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting 11/09/22 Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update 11/08/22 Aadi Bioscience Announces Planned Leadership Transition 11/03/22 Aadi Bioscience to Present at Upcoming Investor Conferences 11/02/22 Aadi Bioscience to Report Third Quarter 2022 Results and Corporate Update 10/27/22 Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium 10/12/22 Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium 10/12/22 Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation 09/22/22 Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing 09/01/22 Aadi Bioscience Announces Participation in Upcoming September Investor Conferences 08/10/22 Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update 07/28/22 Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update 06/23/22 Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes 06/01/22 Aadi Bioscience to Present at the Jefferies Global Healthcare Conference 05/31/22 Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications 05/26/22 Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting 05/18/22 Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference 05/12/22 UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update 05/12/22 Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update 05/09/22 Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders 05/04/22 Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services 04/28/22 Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022 04/18/22 Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit 04/08/22 Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR) 03/31/22 Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes 03/17/22 Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update 03/01/22 Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference 02/23/22 Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa 01/04/22 Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference